|
16 Nov 2021 |
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
|
|
16 Nov 2021 |
NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
|
|
16 Nov 2021 |
AZD8601 EPICCURE Phase II trial demonstrated safety and tolerability in patients with heart failure
|
|
15 Nov 2021 |
LATE BREAKING PRESENTATION AT AMERICAN HEART ASSOCIATION ANNUAL MEETING OF LANDMARK PHASE 3 TRIAL OF REXLEMESTROCEL-L IN CHRONIC HEART FAILURE
|
|
14 Nov 2021 |
Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021
|
|
14 Nov 2021 |
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting
|
|
14 Nov 2021 |
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
|
|
14 Nov 2021 |
AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting
|
|
14 Nov 2021 |
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
|
|
14 Nov 2021 |
Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC
|
|
14 Nov 2021 |
CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing
|
|
14 Nov 2021 |
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting
|
|
14 Nov 2021 |
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
|
|
14 Nov 2021 |
CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
|
|
12 Nov 2021 |
Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
|
|
11 Nov 2021 |
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
|
|
10 Nov 2021 |
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
|
|
08 Nov 2021 |
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration
|
|
08 Nov 2021 |
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
|
|
04 Nov 2021 |
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
|
|
04 Nov 2021 |
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
|
|
04 Nov 2021 |
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
|
|
04 Nov 2021 |
Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference
|
|
04 Nov 2021 |
Memgen Announces FDA Clearance of IND Application for MEM-288
|
|
04 Nov 2021 |
ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference
|
